Abstract

Noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) are follicular-patterned thyroid neoplasms defined by nuclear atypia and indolent behavior. They harbor RAS mutations, rather than BRAFV600E mutations as is observed in papillary thyroid carcinomas with extensive follicular growth. Reliably identifying NIFTPs aids in safe therapy de-escalation, but has proven to be challenging due to interobserver variability and morphologic heterogeneity. The genomic scoring system BRS (BRAF-RAS score) was developed to quantify the extent to which a tumor’s expression profile resembles a BRAFV600E or RAS-mutant neoplasm. We proposed that deep learning prediction of BRS could differentiate NIFTP from other follicular-patterned neoplasms. A deep learning model was trained on slides from a dataset of 115 thyroid neoplasms to predict tumor subtype (NIFTP, PTC-EFG, or classic PTC), and was used to generate predictions for 497 thyroid neoplasms within The Cancer Genome Atlas (TCGA). Within follicular-patterned neoplasms, tumors with positive BRS (RAS-like) were 8.5 times as likely to carry an NIFTP prediction than tumors with negative BRS (89.7% vs 10.5%, P < 0.0001). To test the hypothesis that BRS may serve as a surrogate for biological processes that determine tumor subtype, a separate model was trained on TCGA slides to predict BRS as a linear outcome. This model performed well in cross-validation on the training set (R2 = 0.67, dichotomized AUC = 0.94). In our internal cohort, NIFTPs were near universally predicted to have RAS-like BRS; as a sole discriminator of NIFTP status, predicted BRS performed with an AUC of 0.99 globally and 0.97 when restricted to follicular-patterned neoplasms. BRAFV600E-mutant PTC-EFG had BRAFV600E-like predicted BRS (mean −0.49), nonmutant PTC-EFG had more intermediate predicted BRS (mean −0.17), and NIFTP had RAS-like BRS (mean 0.35; P < 0.0001). In summary, histologic features associated with the BRAF-RAS gene expression spectrum are detectable by deep learning and can aid in distinguishing indolent NIFTP from PTCs.

Highlights

  • Thyroid neoplasms can be broadly categorized as papillary carcinomas or follicular-patterned neoplasms

  • In order to test our hypothesis that NIFTPs are associated with RAS-like BRAF-RAS score (BRS), we began with evaluating slides of thyroid neoplasms in the thyroid cancer cohort (THCA) cohort of The Cancer Genome Atlas (TCGA)

  • Since TCGA annotations do not account for the NIFTP subtype, we created a deep learning model, trained on an institutional dataset to predict thyroid neoplasm subtype, that could generate modern diagnostic predictions for slides in TCGA

Read more

Summary

Introduction

Thyroid neoplasms can be broadly categorized as papillary carcinomas or follicular-patterned neoplasms. Classic papillary thyroid carcinoma (PTC-classic) are infiltrative, often metastasize to lymph nodes, and frequently harbor BRAFV600E mutations (~45%), RET-PTC rearrangements (~20%), and/or a BRAFV600E-like gene expression signature [1,2,3]. Follicular thyroid neoplasms have been described with several historical frameworks. Due to high interobserver variability and observed behavioral heterogeneity, definitions of the various follicular-patterned neoplasms have come under recent attention. Modern descriptions of follicular-patterned neoplasms (excluding conventional follicular adenomas and follicular carcinomas) include three main types: PTC with extensive follicular growth Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular. EFG), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), and invasive encapsulated follicular variant of PTC (IE-PTC-FV) [4, 5]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.